VCM
CLDX icon

Versant Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Versant Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.6K Hold
689
– – ﹤0.01% 1811
2026
Q1 		$21.9K Buy
689
+37
+6% +$1.01K ﹤0.01% 1770
2025
Q4 		$17.7K Buy
652
+438
+205% +$11.5K ﹤0.01% 1718
2025
Q3 		$5.54K Hold
214
– – ﹤0.01% 2172
2025
Q2 		$4.36K Buy
214
+126
+143% +$2.45K ﹤0.01% 2206
2025
Q1 		$1.6K Buy
+88
New +$1.97K ﹤0.01% 2301
2024
Q4 		– Sell
-92
Closed -$3.13K – 2386
2024
Q3 		$3.13K Buy
+92
New +$3.5K ﹤0.01% 1432

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Versant Capital Management's CLDX Position: Q2 2026 in Review

Versant Capital Management held its Celldex Therapeutics (CLDX) position steady in Q2 2026 at 689 shares worth $25.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1811.

Versant Capital Management first reported a position in CLDX in Q3 2024 and has held it in 7 quarters since. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Versant Capital Management held 689 shares of Celldex Therapeutics worth $25.6K as of Q2 2026.
  • Versant Capital Management left its Celldex Therapeutics share count unchanged in Q2 2026.
  • Celldex Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #1811 holding.
  • Versant Capital Management first reported a position in Celldex Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.